Table 1.
Author | Fertsch [15] | Cohen [16] | Calabrese [17] | Cogliandro [18] | Khan [19] | Krastev [20] | Kronowitz [21] | |
Type of study | Case-control | Cohort | Cohort | Cohort | Case-control | Cohort | Cohort | |
Year | 2017 | 2017 | 2018 | 2017 | 2017 | 2019 | 2015 | |
Number of patients | 200 | 829 | 233 | 70 | 71 | 587 | 2364 | |
Number of cases | 100 | 248 | 105 | 46 | 32 | 300 | 1024 | |
Age | ||||||||
AFG | 49.6 | 47,8/48,1a | 48,8/50,3b | 41c | 49 | 48.1 | 47,7/45,8a | |
No AFG | 50.7 | 52,6/49a | 47,7 | 41c | 54 | 49.4 | 46,5 | |
Follow up (months) | ||||||||
AFG | 72.5 | 45,6/42,5a | 84/75b | 30c | 36 | 112 | 59,6/73,5a | |
No AFG | 76.5 | 38,8/37,6a | 72 | 30c | 36 | 103 | 43.8 | |
Stage | ||||||||
Stage 0 - AFG | 9 | 51/NAa | 5/9b | NA | NA | 39 | 174/16a | |
Stage 0 - no AFG | 9 | 83/NAa | 6 | NA | NA | 40 | 115 | |
Stage 1 - AFG | NA | 55/NAa | 16/38b | NA | NA | 99 | 266/14a | |
Stage 1 no AFG | NA | 149/NAa | 26 | NA | NA | 102 | 208 | |
Stage 2 AFG | NA | 46/NAa | 20/17b | NA | NA | 114 | 199/23a | |
Stage 2 no AFG | NA | 143/NAa | 32 | NA | NA | 107 | 245 | |
Stage 3 AFG | NA | 10/NAa | 0 | NA | NA | 48 | 65/6a | |
Stage 3 no AFG | NA | 39/NAa | 0 | NA | NA | 51 | 92 | |
Prophylactic surgery | No | No/Yes | No | No | No | No | No/Yes | |
Breast Reconstruction Type | DIEP | Tissue expander or Autologous or Implant | Tissue expander + Implant | Implant | NA | NA | NA | |
AFG technique | Coleman | Coleman | Coleman + SVF | Coleman | Coleman | Coleman | NA | |
Author | Masia [22] | Stumpf [23] | Sorrentino [24] | Silva-Vergara [25] | Seth [5] | Petit DCIS [26] | Petit Invasive [27] | Mazur [28] |
Type of study | Cohort | Cohort | Cohort | Cohort | Cohort | Case-control | Case-control | Case-control |
Year | 2015 | 2017 | 2019 | 2017 | 2012 | 2013 | 2012 | 2018 |
Number of patients | 214 | 194 | 830 | 615 | 886 | 177 | 963 | 308 |
Number of cases | 107 | 27 | 233 | 205 | 69 | 59 | 321 | 56 |
Age | ||||||||
AFG | 49.2 | 53.6 | 49.4 | 49.1 | 49.4 | 46 | 45 | NA |
No AFG | 48.9 | 56 | 51 | 50 | 48 | 47 | 46 | NA |
Follow up (months) | ||||||||
AFG | 89 | 36 | 74.1 | 88.7 | 43.6 | 63 | 56 | 36 |
No AFG | 120 | 36 | 63.8 | 86.8 | 42.1 | 66 | 57 | NA |
Stage | ||||||||
Stage 0 - AFG | 61 | 0 | 31 | 0 | 17 | 59 | 37 | NA |
Stage 0 - no AFG | 69 | 0 | 71 | 0 | 176 | 118 | 74 | NA |
Stage 1 - AFG | 23 | 7 | 94 | 109 | 23 | 0 | 174 | NA |
Stage 1 no AFG | 26 | 78 | 289 | 237 | 212 | 0 | 348 | NA |
Stage 2 AFG | 14 | 20 | 71 | 79 | 23 | 0 | 86 | NA |
Stage 2 no AFG | 5 | 89 | 178 | 135 | 288 | 0 | 172 | NA |
Stage 3 AFG | 5 | 0 | 37 | 11 | 4 | 0 | 24 | NA |
Stage 3 no AFG | 2 | 0 | 58 | 23 | 87 | 0 | 48 | NA |
Prophylactic surgery | No | No | No | No | No | No | No | NA |
Breast Reconstruction Type |
DIEP, SIEA, SGAP, IGAP, TAP |
Breast conserving surgery plus AFG | NA | NA | NA | NA | NA | NA |
AFG technique | Coleman | Coleman | Coleman | Coleman | Coleman | Coleman | NA | Coleman |
AFG Autologous fat grafting, DIEP deep inferior epigastric artery perforator flap, IGAP inferior gluteal artery perforator flap, NA not available, SGAP superior gluteal artery perforator flap, SIEA superficial inferior epigastric artery flap, SVF stromal vascular fraction, TAP thoracodorsal artery perforator flap
a in Cohen et al. and Kronowitz et at, the authors performed AFG for patients that undergone cancer surgery and prophylactic surgery. In these studies, the number on the left refers to the patients that undergone cancer surgery and the number on the right refers to the patients that undergone prophylactic surgery
b in Calabrese et al., the authors employed two modalities of AFG. The number on the left refers to the patients that undergone AFG with adipose tissue enriched with stem cells from the stromal vascular fraction. The number on the right refers to classic Coleman AFG technique
c in Cogliandro et al., the authors do not present the age and follow-up according to study groups; they only present the mean age and mean follow-up for the whole population